Pacira BioSciences, Inc.

DB:82P Stock Report

Market Cap: €863.8m

Pacira BioSciences Valuation

Is 82P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 82P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 82P (€18.2) is trading below our estimate of fair value (€83.66)

Significantly Below Fair Value: 82P is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 82P?

Key metric: As 82P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 82P. This is calculated by dividing 82P's market cap by their current revenue.
What is 82P's PS Ratio?
PS Ratio1.3x
SalesUS$694.96m
Market CapUS$898.99m

Price to Sales Ratio vs Peers

How does 82P's PS Ratio compare to its peers?

The above table shows the PS ratio for 82P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
DMP Dermapharm Holding
1.7x4.1%€2.0b
PSG PharmaSGP Holding
2.5x7.3%€287.8m
2FJ0 Pierrel
3.4xn/a€92.8m
0RX Redx Pharma
13.3x-37.6%€65.0m
82P Pacira BioSciences
1.3x0.6%€899.0m

Price-To-Sales vs Peers: 82P is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 82P's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
82P 1.3xIndustry Avg. 3.2xNo. of Companies19PS048121620+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 82P is good value based on its Price-To-Sales Ratio (1.3x) compared to the European Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is 82P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

82P PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: 82P is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 82P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.20
€17.13
-5.9%
49.8%€36.86€7.56n/a8
Dec ’25€15.70
€16.89
+7.6%
50.7%€36.61€7.51n/a8
Nov ’25€15.50
€16.86
+8.7%
51.5%€35.53€7.29n/a8
Oct ’25€13.40
€16.44
+22.7%
52.1%€34.90€7.16n/a8
Sep ’25€13.80
€16.37
+18.6%
53.6%€35.47€7.28n/a8
Aug ’25€18.80
€35.63
+89.5%
23.7%€52.82€23.17n/a9
Jul ’25€26.60
€41.26
+55.1%
14.9%€52.38€33.08n/a10
Jun ’25€28.00
€41.26
+47.4%
14.9%€52.38€33.08n/a10
May ’25€23.80
€41.38
+73.9%
14.3%€52.06€32.88n/a10
Apr ’25€26.80
€41.38
+54.4%
14.3%€52.06€32.88n/a10
Mar ’25€26.80
€42.04
+56.9%
14.3%€52.60€35.07n/a9
Feb ’25€29.80
€44.12
+48.0%
13.6%€52.75€35.17n/a9
Jan ’25€30.20
€44.09
+46.0%
14.0%€52.84€34.62n/a10
Dec ’24€24.80
€44.71
+80.3%
13.8%€52.80€34.59€15.709
Nov ’24€26.20
€51.27
+95.7%
11.9%€62.83€43.14€15.509
Oct ’24€28.80
€50.72
+76.1%
11.9%€61.95€41.91€13.409
Sep ’24€32.40
€50.72
+56.5%
11.9%€61.95€41.91€13.809
Aug ’24€32.80
€55.53
+69.3%
15.1%€71.91€43.15€18.809
Jul ’24€36.40
€57.70
+58.5%
14.2%€73.26€45.79€26.609
Jun ’24€35.00
€58.74
+67.8%
15.3%€72.63€45.40€28.0010
May ’24€40.40
€59.43
+47.1%
15.5%€72.92€45.58€23.8010
Apr ’24€37.00
€61.38
+65.9%
16.2%€74.62€46.64€26.8010
Mar ’24€40.80
€61.39
+50.5%
19.0%€84.41€46.90€26.8011
Feb ’24€36.40
€61.63
+69.3%
18.6%€82.79€46.00€29.8011
Jan ’24€36.20
€68.24
+88.5%
15.7%€84.76€47.09€30.2011
Dec ’23€45.80
€73.01
+59.4%
14.3%€89.34€53.61€24.8011

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Balaji PrasadBarclays
Anita DushyanthBerenberg